Prospective Observational Long-term Safety Registry of Multiple Sclerosis Participants Who Have Participated in Cladribine Clinical Trials

Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)

NCT03961204 ·Status: COMPLETED ·Phase: PHASE4

Effect of Cladribine Treatment on Microglial Activation in the CNS

NCT04239820 ·Status: ACTIVE_NOT_RECRUITING

Study of the Mechanisms of Action of Cladribine in Multiple Sclerosis

NCT04821596 ·Status: COMPLETED ·Phase: NA

Oral Cladribine in Early Multiple Sclerosis (MS)

NCT00725985 ·Status: COMPLETED ·Phase: PHASE3

A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

NCT00529581 ·Status: COMPLETED ·Phase: PHASE2

Cladribine Tablets After Treatment With Natalizumab (CLADRINA)

NCT04178005 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis

NCT01435993 ·Status: TERMINATED ·Phase: PHASE1

Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients

NCT05902429 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns

NCT01930799 ·Status: COMPLETED ·Phase: PHASE4

A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)

NCT00436826 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis

NCT01433250 ·Status: COMPLETED ·Phase: PHASE2

Consolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients

NCT06854094 ·Status: ACTIVE_NOT_RECRUITING

First-in-Human Study With GNbAC1 in Healthy Volunteers

NCT01699555 ·Status: COMPLETED ·Phase: PHASE1

MS-ResearchBiomarkerS

NCT05204459 ·Status: RECRUITING

A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period

NCT02587195 ·Status: COMPLETED ·Phase: PHASE3

Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis

NCT05061953 ·Status: RECRUITING

Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients

NCT00262314 ·Status: COMPLETED

Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis

NCT02040298 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy

NCT04640818 ·Status: UNKNOWN

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT01194570 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis

NCT02280096 ·Status: COMPLETED ·Phase: PHASE2

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

NCT05961644 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis

NCT00097331 ·Status: COMPLETED ·Phase: PHASE2

Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)

NCT04934800 ·Status: COMPLETED

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

NCT05359653 ·Status: RECRUITING ·Phase: PHASE1/PHASE2